Patents Examined by Brian McDowell
  • Coelenterazine derivatives and methods of using same
    Patent number: 9487520
    Abstract: The invention provides coelenterazine derivatives which are substrates for a non-luminescent enzyme and a pro-substrate for a luminescent enzyme. The invention also provides a method of using the derivatives.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: November 8, 2016
    Assignee: PROMEGA CORPORATION
    Inventors: Dieter H. Klaubert, Poncho Meisenheimer, James Unch, Wenhui Zhou
  • Pyrazole compound and pesticidal mixtures comprising a pyrazole compound
    Patent number: 9474277
    Abstract: The present invention relates to pesticidal mixtures comprising as active compounds 1) at least one pyrazole compound A selected from the compounds of formula I: wherein the variables have the meaning as defined in the description, and 2) at least one further compound B selected from the compounds of the following groups A.1, A.2, A.3, A.4, A.5, A.6, A.7, A.8, A.9, A.10, A.11, A.12, A.13, A.14, A.15, A.16, A.17, F.1, F.2, F.3, F.4, F.5, F.6, F.7, F.8, F.9, F.10 and F.11 as defined in the specification. The present invention also relates to novel pyrazole compounds of the formula I. The present invention also relates to methods and use of these mixtures and novel compounds for combating invertebrate pests such as insects, arachnids or nematodes in and on plants, and for protecting such plants being infested with pests, especially also for protecting plant propagation material as like seeds.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: October 25, 2016
    Assignee: BASF SE
    Inventors: Sebastian Soergel, Daniel Saelinger, Christian Defieber, Juergen Langewald, Birgit Gockel, Egon Haden, Deborah L. Culberston, Koshi Gunjima
  • Synthesis of triazolopyrimidine compounds
    Patent number: 9469614
    Abstract: The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: October 18, 2016
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Borut Zupancic, Nenad Maras, Damjan Sterk
  • Bicyclic oxa-lactam kinase inhibitors
    Patent number: 9469654
    Abstract: Provided are bicyclic oxa-lactam compounds of formula I: and pharmaceutically acceptable salts thereof which are inhibitors of JAK/Syk kinase. The present disclosure is also directed to intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: October 18, 2016
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Anjali Pandey, Yonghong Song, Qing Xu
  • DOT1L inhibitors
    Patent number: 9458165
    Abstract: Provided herein are inhibitors of DOT1L of formula (I) useful for treating diseases or disorders associated with DOT1L: in which R1 is defined in the specification. An exemplary DOT1L inhibitor provided herein exhibits a biological half-life of 12.6 h. Methods for treating diseases associated with DOT1L are also provided.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: October 4, 2016
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Jun Qi, Alexander Federation
  • Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof
    Patent number: 9452220
    Abstract: The present invention discloses coupling compounds of a structure as shown in Formula I, II or III formed by connecting NSAID anti-inflammatory and analgesic drugs and EGFR inhibitors by ester bonds or pharmaceutically acceptable salts or stereoisomers thereof or prodrug molecules thereof: where R is a NSAID anti-inflammatory and analgesic drug. In the present invention, the coupling compounds obtained by coupling NSAID anti-inflammatory and analgesic drugs with EGFR inhibitors have excellent therapeutic effects of tumors and provide new drugs for clinic treatment options.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: September 27, 2016
    Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
    Inventors: Yanmei Zhang, Ke Ding, Jinxi Liao, Yican Wang, Panyu Chen
  • (Bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders
    Patent number: 9452172
    Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: September 27, 2016
    Assignee: Yeda Research and Development Co. LTD.
    Inventors: Avigdor Joshua Scherz, Yoram Salomon, Arie Marcovich, Alexander Brandis, Daniel Wagner
  • Inhibitor of p38 map kinase
    Patent number: 9447076
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 20, 2016
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Kinase modulators
    Patent number: 9421209
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: August 23, 2016
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
  • Process for preparing 11-methylene-18-methyl-estr-4-en-3, 17-dione, useful as intermediate compound for the synthesis of molecules having pharmacological activity
    Patent number: 9422326
    Abstract: There is described a process for the industrial synthesis of 11-methylene-18-methyl-estr-4-en-3,17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of the progestin compounds Desogestrel and Etonogestrel.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: August 23, 2016
    Assignee: INDUSTRIALE CHIMICA S.r.l.
    Inventors: Roberto Lenna, Edoardo Mariani, Andrea Vanossi
  • Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
    Patent number: 9416111
    Abstract: The invention provides certain substituted diazine and triazine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: August 16, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew M. Haidle, Michael D. Altman, Solomon D. Kattar, Matthew Christopher, John Michael Ellis, Christian Fischer, Alan B. Northrup, Kaleen Konrad Childers
  • ?-form zinc-phthalocyanine nanowires having enhanced water solubility and water dispersibility, composite of an ?-form zinc-phthalocyanine nanowire/phenothiazine, and method for preparing same
    Patent number: 9415106
    Abstract: The present invention relates to alpha-form zinc-phthalocyanine nanowires (ZnPc NWs) having enhanced water solubility and water dispersibility, to a composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, to a method for preparing same, and to a photosensitizer including same or a pharmaceutical composition including same for preventing or treating cancers. Since the alpha-form zinc-phthalocyanine nanowires or the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine according to the present invention exhibit dual traits, i.e., photothermal and photodynamic traits in single molecules, they are very useful for the development of a multifunctional molecular system and can also be usefully applied to light therapy of cancers due to their good light therapeutic effects.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: August 16, 2016
    Assignee: POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY INDUSTRY ACADEMY COOPERATION CORPS
    Inventors: Hee Cheul Choi, Hye Kyung Moon, Sang Ho Lee
  • Carbocycle-substituted purine and 7-deazapurine compounds
    Patent number: 9394310
    Abstract: The present invention relates to carbocycle-substituted purine and 7-deazapurine compounds of Formula (I). The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: July 19, 2016
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz
  • Imidazo pyridine compounds
    Patent number: 9394317
    Abstract: The present invention provides compounds of the formula I, wherein X is a bond or CH2; Q is CH2 or O; L is selected from the group consisting of —OCH2— and —CH2O—; or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: July 19, 2016
    Assignee: Eli Lilly and Company
    Inventors: Spencer Brian Jones, Bryan Hurst Norman, Lance Allen Pfeifer
  • Substituted aminoquinazolines useful as kinases inhibitors
    Patent number: 9388170
    Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: July 12, 2016
    Inventors: Xiaoyang Xia, Dawei Zhang
  • Dihydropyridone P1 as factor XIa inhibitors
    Patent number: 9376444
    Abstract: The present invention provides compounds of Formula (VIII): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: June 28, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wu Yang, James R. Corte, Paul J. Gilligan, Donald J. P. Pinto, William R. Ewing, Yufeng Wang
  • Pyrrolobenzodiazepines as antiproliferative agents
    Patent number: 9376440
    Abstract: Novel pyrrolobenzodiazepines (PBDs) having a (1-methyl-1H-pyrrol-3-yl)phenyl based amino acid residue and use thereof as antiproliferative agents are disclosed herein.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: June 28, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, David Edwin Thurston, Khondaker Mirazur Rahman
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 9370522
    Abstract: Disclosed herein are new heterocyclic compounds having structural Formula IIa and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 21, 2016
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Michael Clare
  • Pyrazine kinase inhibitors
    Patent number: 9359308
    Abstract: Provided are pyrazine compounds of Formula (I) for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: June 7, 2016
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Yonghong Song, Qing Xu, Zhaozhong J. Jia, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • 17a-hydroxylase/C17,20-lyase inhibitors
    Patent number: 9339501
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 17, 2016
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta